Raymond James Financial
NVCR icon

Raymond James Financial’s NovoCure NVCR Stock Holding History

Raymond James Financial’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,842
Closed -$68.4K – 6143
2025
Q2 		$68.4K Sell
3,842
-7,820
-67% -$136K ﹤0.01% 5054
2025
Q1 		$208K Sell
11,662
-10
-0.1% -$227 ﹤0.01% 4404
2024
Q4 		$348K Buy
+11,672
New +$247K ﹤0.01% 4100

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raymond James Financial's NVCR Position: Q3 2025 in Review

Raymond James Financial sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 3,842 shares — an estimated $68.4K sold.

Raymond James Financial first reported a position in NVCR in Q4 2024 and held it in 3 quarters. The position peaked at $348K in Q4 2024. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Raymond James Financial reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 3,842 NovoCure shares in Q3 2025, an estimated $68.4K.
  • Raymond James Financial first reported a position in NovoCure in Q4 2024 and held it in 3 quarters.
  • Raymond James Financial's NovoCure position peaked at $348K in Q4 2024.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.